Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2021 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS, Stock Up 2.92%

Arrowhead Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by nearly 3% following the earnings report, likely due to optimism about their ongoing projects and pipeline developments. Investors may be viewing the long-term potential favorably despite the current EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.29	N/A	-253.66%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the challenges faced this quarter, particularly with EPS. They emphasized their commitment to pipeline development.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on advancing their pipeline despite the EPS miss.

Arrowhead Pharmaceuticals Misses on EPS, Stock Up 2.92%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS, Stock Up 2.92%

Key numbers

Management commentary